{"id":"atenolol-succinate-oral-tablet","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Cold extremities"},{"rate":"3-5","effect":"Dyspnea"},{"rate":"2-5","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL24","moleculeType":"Small molecule","molecularWeight":"266.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atenolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart rate, contractility, and cardiac output. This leads to reduced blood pressure and myocardial oxygen demand. The succinate salt formulation is an extended-release variant designed to provide sustained therapeutic levels.","oneSentence":"Atenolol succinate is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:48.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Acute myocardial infarction"},{"name":"Atrial fibrillation for rate control"}]},"trialDetails":[{"nctId":"NCT04914234","phase":"PHASE4","title":"Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries","status":"RECRUITING","sponsor":"Damanhour Teaching Hospital","startDate":"2025-08-01","conditions":"Hypotension Drug-Induced","enrollment":60},{"nctId":"NCT03278509","phase":"PHASE4","title":"Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2017-09-11","conditions":"Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tenormin tablets"],"phase":"marketed","status":"active","brandName":"Atenolol Succinate Oral Tablet","genericName":"Atenolol Succinate Oral Tablet","companyName":"Damanhour Teaching Hospital","companyId":"damanhour-teaching-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atenolol succinate is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart. Used for Hypertension, Angina pectoris, Acute myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}